Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Experts Weigh In On Zocor “Pharmacy Status” In UK, Prospects For U.S. Statin Switch

This article was originally published in The Tan Sheet

Executive Summary

Four experts in cardiovascular medicine participated in May 13 interviews with "The Tan Sheet" to discuss the UK's decision to switch Merck's Rx cholesterol-lowering drug Zocor (10 mg simvastatin) to behind-the-counter availability. Below are excerpts from conversations with PROVE-IT trial [comparing Pfizer's Lipitor with Bristol-Myers Squibb's Pravachol] principal investigator Chris Cannon, MD, Brigham & Women's Hospital in Boston; Eric Topol, MD, Cleveland Clinic Foundation; Drug Safety & Risk Management Advisory Committee member Brian Strom, MD, University of Pennsylvania Medical School; and former Nonprescription Drugs Advisory Committee Chairman Eric Brass, MD/PhD, UCLA School of Medicine. Brass chaired the committee during its 2000 consideration of switches for Mevacor and Pravachol and currently is a paid consultant for Johnson & Johnson/Merck

You may also be interested in...



Mevacor OTC Actual-Use Study Data May Answer Future NDAC Questions

Nearly half of high-risk patients in the Mevacor OTC actual-use study took the low-dose statin only after securing approval from a doctor, writes Eric Brass, MD/PhD, UCLA Medical Center, in a supplement to the Nov. 15 American Journal of Cardiology

Mevacor OTC Actual-Use Study Data May Answer Future NDAC Questions

Nearly half of high-risk patients in the Mevacor OTC actual-use study took the low-dose statin only after securing approval from a doctor, writes Eric Brass, MD/PhD, UCLA Medical Center, in a supplement to the Nov. 15 American Journal of Cardiology

Mevacor OTC Actual-Use Study Data May Answer Future NDAC Questions

Nearly half of high-risk patients in the Mevacor OTC actual-use study took the low-dose statin only after securing approval from a doctor, writes Eric Brass, MD/PhD, UCLA Medical Center, in a supplement to the Nov. 15 American Journal of Cardiology

Topics

UsernamePublicRestriction

Register

LL1125120

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel